Cargando…

Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin

AIMS: Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose‐cotransporter 2 inhibitors (SGLT2‐is) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsubayashi, Yasuhiro, Yoshida, Akihiro, Suganami, Hideki, Osawa, Taeko, Furukawa, Kazuo, Suzuki, Hiroshi, Fujihara, Kazuya, Tanaka, Shiro, Kaku, Kohei, Sone, Hirohito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318197/ https://www.ncbi.nlm.nih.gov/pubmed/31984623 http://dx.doi.org/10.1111/dom.13980

Ejemplares similares

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2021)

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2022)

Dipeptidyl peptidase‐4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
por: Abe, Takahiro, et al.
Publicado: (2021)

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
por: Nunoi, Kiyohide, et al.
Publicado: (2019)

Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
por: Nunoi, Kiyohide, et al.
Publicado: (2018)

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance
por: Nojima, T., et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
por: Tobe, Kazuyuki, et al.
Publicado: (2017)

Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss
por: Sato, Yuichi, et al.
Publicado: (2019)

Pulse Pressure is a Stronger Predictor Than Systolic Blood Pressure for Severe Eye Diseases in Diabetes Mellitus
por: Yamamoto, Masahiko, et al.
Publicado: (2019)

Rates and risk factors for amputation in people with diabetes in Japan: a historical cohort study using a nationwide claims database
por: Kaneko, Masanori, et al.
Publicado: (2021)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Retrospective cohort study to examine the association between serum amylase and the incidence of type 2 diabetes mellitus, Toranomon Hospital Health Management Center Study 23 (TOPICS 23)
por: Ikeda, Izumi, et al.
Publicado: (2023)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
por: Kaku, Kohei, et al.
Publicado: (2014)

Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese
por: Oe, Momoko, et al.
Publicado: (2021)

Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2022)

Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
por: Fujihara, Kazuya, et al.
Publicado: (2018)

Machine Learning Approach to Drug Treatment Strategy for Diabetes Care
por: Fujihara, Kazuya, et al.
Publicado: (2023)

Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42)
por: Fujihara, Kazuya, et al.
Publicado: (2017)

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice
por: Obara, Koki, et al.
Publicado: (2017)

The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
por: Li, Zi, et al.
Publicado: (2020)

The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice
por: Hanaguri, Junya, et al.
Publicado: (2022)

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis
por: Murakami, Kentaro, et al.
Publicado: (2022)

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
por: Kamei, Shinji, et al.
Publicado: (2018)

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
por: Suzuki, M, et al.
Publicado: (2014)

Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes
por: Kakuda, Hirokazu, et al.
Publicado: (2019)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus
por: Higashikawa, Toshihiro, et al.
Publicado: (2020)

Combination of diabetes mellitus and lack of habitual physical activity is a risk factor for functional disability in Japanese
por: Fujihara, Kazuya, et al.
Publicado: (2020)

Machine Learning Approach to Decision Making for Insulin Initiation in Japanese Patients With Type 2 Diabetes (JDDM 58): Model Development and Validation Study
por: Fujihara, Kazuya, et al.
Publicado: (2021)

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)
por: Kaku, Kohei, et al.
Publicado: (2019)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

Ability of Current Machine Learning Algorithms to Predict and Detect Hypoglycemia in Patients With Diabetes Mellitus: Meta-analysis
por: Kodama, Satoru, et al.
Publicado: (2021)

Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J‐STEP/EL): A 12‐week interim analysis
por: Utsunomiya, Kazunori, et al.
Publicado: (2016)

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post‐marketing study (J‐STEP/EL Study)
por: Utsunomiya, Kazunori, et al.
Publicado: (2017)

Physical Fitness and Dyslipidemia Among Japanese: A Cohort Study From the Niigata Wellness Study
por: Momma, Haruki, et al.
Publicado: (2021)

Association of Helicobacter pylori Infection with Glycemic Control in Patients with Diabetes: A Meta-Analysis
por: Horikawa, Chika, et al.
Publicado: (2014)

Reversible brain atrophy and cognitive impairment in an adolescent Japanese patient with primary adrenal Cushing’s syndrome
por: Ohara, Nobumasa, et al.
Publicado: (2014)

Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Association Between Physical Activity and Risk of All-Cause Mortality and Cardiovascular Disease in Patients With Diabetes: A meta-analysis
por: Kodama, Satoru, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_049b3c1fciot3gnvu54jc50uq8